PortfoliosLab logoPortfoliosLab logo
JAZZ vs. CRSP
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

JAZZ vs. CRSP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Jazz Pharmaceuticals plc (JAZZ) and CRISPR Therapeutics AG (CRSP). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, JAZZ achieves a 35.84% return, which is significantly higher than CRSP's -0.69% return.


JAZZ

1D
2.13%
1M
10.99%
YTD
35.84%
6M
38.20%
1Y
109.33%
3Y*
21.63%
5Y*
5.88%
10Y*
4.22%

CRSP

1D
0.12%
1M
-2.80%
YTD
-0.69%
6M
-6.98%
1Y
36.91%
3Y*
-7.12%
5Y*
-14.40%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

JAZZ vs. CRSP - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
JAZZ
Jazz Pharmaceuticals plc
35.84%38.04%0.12%-22.79%25.05%-22.81%10.56%20.43%-7.94%23.50%
CRSP
CRISPR Therapeutics AG
-0.69%33.23%-37.12%54.00%-46.36%-50.51%151.39%113.18%21.68%15.89%

Correlation

The correlation between JAZZ and CRSP is 0.32, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.32

Correlation (3Y)
Calculated over the trailing 3-year period

0.29

Correlation (5Y)
Calculated over the trailing 5-year period

0.32

Correlation (All Time)
Calculated using the full available price history since Oct 20, 2016

0.30

Fundamentals

Market Cap

JAZZ:

$15.26B

CRSP:

$5.00B

EPS

JAZZ:

$0.47

CRSP:

-$6.24

PS Ratio

JAZZ:

3.25

CRSP:

1.16K

PB Ratio

JAZZ:

3.37

CRSP:

2.76

Total Revenue (TTM)

JAZZ:

$4.44B

CRSP:

$4.10M

Gross Profit (TTM)

JAZZ:

$2.97B

CRSP:

-$171.17M

EBITDA (TTM)

JAZZ:

$336.83M

CRSP:

-$509.21M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

JAZZ vs. CRSP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

JAZZ
JAZZ Risk / Return Rank: 9696
Overall Rank
JAZZ Sharpe Ratio Rank: 9494
Sharpe Ratio Rank
JAZZ Sortino Ratio Rank: 9696
Sortino Ratio Rank
JAZZ Omega Ratio Rank: 9595
Omega Ratio Rank
JAZZ Calmar Ratio Rank: 9797
Calmar Ratio Rank
JAZZ Martin Ratio Rank: 9696
Martin Ratio Rank

CRSP
CRSP Risk / Return Rank: 5858
Overall Rank
CRSP Sharpe Ratio Rank: 6060
Sharpe Ratio Rank
CRSP Sortino Ratio Rank: 6060
Sortino Ratio Rank
CRSP Omega Ratio Rank: 5656
Omega Ratio Rank
CRSP Calmar Ratio Rank: 5959
Calmar Ratio Rank
CRSP Martin Ratio Rank: 5555
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

JAZZ vs. CRSP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Jazz Pharmaceuticals plc (JAZZ) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


JAZZCRSPDifference
Sharpe ratioReturn per unit of total volatility

+2.38

Sortino ratioReturn per unit of downside risk

+3.26

Omega ratioGain probability vs. loss probability

1.57

1.15

+0.43

Calmar ratioReturn relative to maximum drawdown

9.63

0.88

+8.75

Martin ratioReturn relative to average drawdown

23.75

1.49

+22.26

JAZZ vs. CRSP - Sharpe Ratio Comparison

The current JAZZ Sharpe Ratio is 2.98, which is higher than the CRSP Sharpe Ratio of 0.60. The chart below compares the historical Sharpe Ratios of JAZZ and CRSP, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


JAZZCRSPDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

2.98

0.60

+2.38

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.19

-0.24

+0.43

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.13

Sharpe Ratio (All Time)

Calculated using the full available price history

0.19

0.23

-0.04

Drawdowns

JAZZ vs. CRSP - Drawdown Comparison

The maximum JAZZ drawdown since its inception was -96.90%, which is greater than CRSP's maximum drawdown of -85.11%. Use the drawdown chart below to compare losses from any high point for JAZZ and CRSP.


Loading charts...

Drawdown Indicators


JAZZCRSPDifference

Max Drawdown

Largest peak-to-trough decline

-96.90%

-85.11%

-11.79%

Max Drawdown (1Y)

Largest decline over 1 year

-11.42%

-42.25%

+30.83%

Max Drawdown (3Y)

Largest decline over 3 years

-32.71%

-64.91%

+32.20%

Max Drawdown (5Y)

Largest decline over 5 years

-47.55%

-80.68%

+33.13%

Max Drawdown (10Y)

Largest decline over 10 years

-52.10%

Current Drawdown

Current decline from peak

-3.71%

-75.20%

+71.49%

Average Drawdown

Average peak-to-trough decline

-27.42%

-49.17%

+21.75%

Ulcer Index

Depth and duration of drawdowns from previous peaks

4.62%

24.92%

-20.30%

Volatility

JAZZ vs. CRSP - Volatility Comparison

The current volatility for Jazz Pharmaceuticals plc (JAZZ) is 9.90%, while CRISPR Therapeutics AG (CRSP) has a volatility of 14.90%. This indicates that JAZZ experiences smaller price fluctuations and is considered to be less risky than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


JAZZCRSPDifference

Volatility (1M)

Calculated over the trailing 1-month period

9.90%

14.90%

-5.00%

Volatility (6M)

Calculated over the trailing 6-month period

23.47%

42.49%

-19.02%

Volatility (1Y)

Calculated over the trailing 1-year period

36.89%

61.68%

-24.79%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

31.75%

60.46%

-28.71%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

32.77%

64.27%

-31.50%

Dividends

JAZZ vs. CRSP - Dividend Comparison

Neither JAZZ nor CRSP has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

JAZZ vs. CRSP - Financials Comparison

This section allows you to compare key financial metrics between Jazz Pharmaceuticals plc and CRISPR Therapeutics AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00M1.00B1.20B20222023202420252026
1.07B
1.46M
(JAZZ) Total Revenue
(CRSP) Total Revenue
Values in USD except per share items

Frequently Asked Questions


JAZZ and CRSP have a correlation of 0.32, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CRSP has higher volatility (14.90%) compared to JAZZ (9.90%). In terms of maximum drawdown, JAZZ dropped -96.90% vs CRSP's -85.11%.

JAZZ currently has the higher Sharpe Ratio (2.98 vs 0.60), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for JAZZ and CRSP

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer